DOCS · Doximity, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q1 FY27 earnings call · Aug 6, 2026TL;DR. Doximity reported Q1 FY27 revenue of $156.6M (up 7% YoY) and adjusted EBITDA of $74.8M (48% margin), both beating guidance, while raising full-year revenue guidance by $6M and AI usage accelerated sharply; however, GAAP net income fell sharply and free cash flow declined 34% YoY due to heavy AI investment.
- + FY27 revenue guidance raised by $6M to $671-681M and EBITDA outlook to $309-329M
- + Record AI engagement, with quarterly active workflow prescribers up more than 30% YoY and AI prompt volume up more than 25% QoQ
- + Enterprise health system wins grew to 165 signed clients including 8 top honor roll hospitals, adding Northwestern, Penn Medicine, and University of Michigan
- − Free cash flow declined 34% YoY to $39.6M and operating cash flow declined 32% YoY
- − Adjusted EBITDA declined 6% YoY to $74.8M and adjusted EBITDA margin compressed from 54.7% to 47.7%
- − Non-GAAP gross margin contracted to ~88% from 91% YoY as AI compute spend ramped
- − Q2 FY27 revenue guidance of $170-171M implies only ~1% YoY growth at midpoint due to tough comp and limited AI Search revenue
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $74.8M | fiscal 2027 first quarter | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 47.7% | fiscal 2027 first quarter | — |
|
|
|||
| Free cash flow non-GAAP | $39.6M | fiscal 2027 first quarter | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 41.99M
-62K Purchases of property and equipment
-2.32M Internal-use software development costs
= Free cash flow 39.6M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DOCS
this stock
Doximity, Inc.
|
$4.74B | -35.6% | +13.1% | 31.6 | 6.9% |
|
VEEV
Veeva Systems Inc
|
$45.44B | +26.3% | +28.1% | 45.9 | 3.1% |
|
TEM
Tempus AI, Inc.
|
$15.34B | +29.6% | +83.4% | — | 15.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.20B | -29.7% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.02B | +52.9% | +28.2% | 33.8 | 5.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DOCS | +9.5% | +8.3% | +35.4% | +0.6% | -35.6% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +9.9% | +8.4% | +23.0% | +0.4% | -47.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.